1. Combined PD-L1 Expression in Malignant and Infiltrating Cells Predicts Survival in Hepatocellular Carcinoma with Atezolizumab and Bevacizumab.
- Author
-
Jaejun Lee, Jae-sung Yoo, Ji Won Han, and Pil Soo Sung
- Subjects
- *
CORE needle biopsy , *CANCER cells , *PROGRAMMED death-ligand 1 , *OVERALL survival , *REFERENCE values - Abstract
Background/Aims PD-L1 expression is abundant not only in malignant cells but also in infiltrating cells within the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). This study explored the association between PD-L1 expression in TME and outcomes in HCC patients treated with atezolizumab plus bevacizumab (AB), emphasizing the implications of PD-L1 expression in both malignant and tumor-infiltrating cells. Methods This retrospective study included 72 patients with HCC who underwent percutaneous core needle liver biopsy before AB treatment between September 2020 and December 2023. PD-L1 expression on tumor tissues was assessed using the combined positive score (CPS) with cutoff values of 1 and 10, utilizing antibody clone 22C3 (Dako). Results The distribution of PD-L1 CPS included 24 patients with CPS <1, 33 patients with CPS 1–10, and 15 patients with CPS ≥10. Significant differences in OS were observed across the three groups, with CPS ≥10 showing the highest survival rates (p=0.010). Patients with CPS ≥10 had better OS than those with CPS <10 (mOS 14.8 vs. 8.3 months, p=0.046), and CPS ≥1 had better OS than CPS <1 (p=0.021). For PFS, the CPS ≥10 group had the highest mPFS of 11.0 months among the three groups (p=0.044). Objective response rates (ORR) were higher in the PD-L1 CPS ≥10 group than in the 1-10 and <1 group (53.3%, 27.3%, and 16.7%, respectively; p=.047). Multivariate analysis identified that PD-L1 expression ≥10 and ≥1 were associated with favorable outcomes regarding OS (hazard ratio [HR] 0.283, p=.027 and HR 0.303, p=.006, respectively). Conclusion Higher PD-L1 expression in malignant and tumor-infiltrating cells was associated with better OS, PFS, and ORR in patients with HCC treated with AB. [ABSTRACT FROM AUTHOR]
- Published
- 2024